Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
boston top stories
deals
4
×
life sciences
national blog main
san francisco blog main
4
×
clinical trials
national top stories
san francisco top stories
boston
cancer drugs
investing
new york blog main
new york top stories
abbvie
acute myeloid leukemia
allergan
alx oncology
alzheimer's disease
amgen
autoimmune diseases
azacitidine
berkeley lights
beta-thalassemia
biotech ipos
cancer
cancer immunotherapy
cd47
chronic kidney disease
cobimetinib
crispr
cynthia collins
dacogen
decitabine
deerfield healthcare technology acquisitions
deerfield management company
dna
editas medicine
epigenetics
What
research
4
×
biotech
medicines
ipo
new
abbvie
aims
alliance
approach
arrival
based
called
cancer
companies
days
debuts
despite
developing
drug
drugs
editas
editing
epigenetic
epigenetics
exits
experimental
family
field
flagship’s
gene
genetic
hardest
hasn’t
hit
hottest
hunters
industry
ipos
life
market
Language
unset
Current search:
biotech
×
" san francisco blog main "
×
deals
×
research
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further